What are the most commonly used alternatives to Keytruda (pembrolizumab)?
Keytruda (pembrolizumab) is used across multiple cancers, so “alternatives” usually means other immune-checkpoint therapies used in similar settings. The most commonly used options include other anti–PD-1/PD-L1 drugs and, depending on the cancer type, combinations with anti–CTLA-4 therapy.
Commonly used alternatives include:
- Opdivo (nivolumab)
- Tecentriq (atezolizumab)
- Imfinzi (durvalumab)
- Bavencio (avelumab)
- Imjudo (tremelimumab) in combination regimens for some cancers (anti–CTLA-4)
How do clinicians choose between these PD-1/PD-L1 alternatives?
Choice usually depends on the cancer type and line of therapy (first-line vs later), plus factors such as tumor PD-L1 status, prior treatments, and whether the treatment plan uses monotherapy or combination immunotherapy. Many patients are switched within the class when disease progression or intolerance occurs.
What are common “next options” if someone stops Keytruda?
If Keytruda is stopped for progression, clinicians often consider:
- Switching to another PD-1 or PD-L1 inhibitor (for example, Opdivo or Tecentriq, depending on indication and access)
- Using a different immunotherapy strategy, such as adding anti–CTLA-4 therapy (e.g., tremelimumab in combination regimens for certain cancers)
- Moving to non–checkpoint options (targeted therapy, chemotherapy, or other agents), depending on the tumor’s biomarkers and prior regimens
Are these alternatives better or just different?
They are not interchangeable across all cancers. Even though they target related immune checkpoints, outcomes and side-effect profiles can differ by tumor type and by regimen. In practice, selection is indication-specific rather than one drug being universally “better.”
Are generics/biosimilars a common alternative to Keytruda?
Keytruda is a biologic, so the practical “alternative” landscape is mostly other branded biologics in similar classes. Biosimilar availability depends on approvals in each region and on the specific product.
If you tell me the cancer type (for example, melanoma, lung, head and neck, kidney, bladder, etc.) and whether it’s first-line or later treatment, I can narrow this to the most used alternative(s) in that exact setting.